Lachesis Biosciences Revenue
Biotechnology Research • 
Melbourne, Victoria, Australia • 1-10 Employees
Lachesis Biosciences revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | No funding |
Key Contact at Lachesis Biosciences
Dr Simone Scovell
Non Executive Director
Company overview
| Headquarters | 664 Collins St, Level 13, Docklands, Victoria 3008, AU |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Employees | 1-10 |
About Lachesis Biosciences
Lachesis BioSciences is a clinical-stage biotechnology company targeting dementia caused by Alzheimer’s and Parkinson’s disease. Lachesis Biosciences is developing LBIO-R32, a rivastigmine nasal spray for the treatment of mild to severe Alzheimer's disease dementia and mild to moderate Parkinson’s disease dementia. Lachesis is pursuing a 505(b)(2) development pathway for LBIO-R32, which means the company can substantially rely on existing preclinical and clinical data generated by Novartis with rivastigmine for approval. From a development standpoint, this takes years and hundreds of millions off their plate. It's a significantly de-risked and expedited approach.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Lachesis Biosciences has never raised funding before.
Belgium
Germany
United Kingdom
United StatesFrequently asked questions
4.8
40,000 users
